- Home
- CRDF vs EPSN Comparison
CRDF vs EPSN Comparison
Compare CRDF & EPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- EPSN
- Stock Information
- Founded
- CRDF 1999
- EPSN 2005
- Country
- CRDF United States
- EPSN Canada
- Employees
- CRDF N/A
- EPSN N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- EPSN Oil & Gas Production
- Sector
- CRDF Health Care
- EPSN Energy
- Exchange
- CRDF Nasdaq
- EPSN Nasdaq
- Market Cap
- CRDF 144.4M
- EPSN 124.0M
- IPO Year
- CRDF N/A
- EPSN N/A
- Fundamental
- Price
- CRDF $2.05
- EPSN $5.46
- Analyst Decision
- CRDF Strong Buy
- EPSN Strong Buy
- Analyst Count
- CRDF 5
- EPSN 1
- Target Price
- CRDF $11.10
- EPSN $7.00
- AVG Volume (30 Days)
- CRDF 1.1M
- EPSN 114.5K
- Earning Date
- CRDF 11-06-2025
- EPSN 11-05-2025
- Dividend Yield
- CRDF N/A
- EPSN 4.54%
- EPS Growth
- CRDF N/A
- EPSN N/A
- EPS
- CRDF N/A
- EPSN 0.23
- Revenue
- CRDF $545,000.00
- EPSN $44,016,087.00
- Revenue This Year
- CRDF N/A
- EPSN $41.35
- Revenue Next Year
- CRDF N/A
- EPSN N/A
- P/E Ratio
- CRDF N/A
- EPSN $23.86
- Revenue Growth
- CRDF N/A
- EPSN 45.90
- 52 Week Low
- CRDF $1.90
- EPSN $4.95
- 52 Week High
- CRDF $5.64
- EPSN $8.50
- Technical
- Relative Strength Index (RSI)
- CRDF 36.50
- EPSN 35.92
- Support Level
- CRDF $2.03
- EPSN $5.45
- Resistance Level
- CRDF $2.27
- EPSN $5.99
- Average True Range (ATR)
- CRDF 0.12
- EPSN 0.18
- MACD
- CRDF 0.04
- EPSN -0.01
- Stochastic Oscillator
- CRDF 31.91
- EPSN 1.67
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.